After a years-long revenue drought, there's a light at the end of the tunnel.
The U.S. government on Tuesday named the 15 new drugs targeted for Medicare price negotiations for 2028, including Gilead ...
In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...
Centers for Medicare & Medicaid Services on Tuesday named a new group of branded drugs from major pharmaceutical ...
Also: All the news and watercooler chat from Fortune.
Jan 27 (Reuters) - The U.S. Centers for Medicare & Medicaid Services on Tuesday named the 15 new drugs targeted for Medicare ...
The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.
Pfizer Inc. has a rare 3-year tariff exemption and margin defense amid global price parity risks. Click here to read an ...
Consumer advocacy organization Public Citizen has filed (PDF) a Freedom of Information Act (FOIA) lawsuit against the Department of Health and Human Services (HHS) and the Department of Commerce (DOC) ...
Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
But while the rankings held steady, the operating environment has changed quickly to reinforce the value of being in good ...
Dr. Albert Bourla became Pfizer’s CEO months before the COVID-19 pandemic took hold of the US. Under his leadership, Pfizer manufactured 3 billion doses of the first FDA-approved vaccine in the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results